10.09
Roivant Sciences Ltd stock is traded at $10.09, with a volume of 7.33M.
It is down -2.79% in the last 24 hours and down -6.05% over the past month.
See More
Previous Close:
$10.38
Open:
$10.18
24h Volume:
7.33M
Relative Volume:
1.48
Market Cap:
$7.73B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.7858
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-6.83%
1M Performance:
-6.05%
6M Performance:
-12.56%
1Y Performance:
-4.27%
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
10.09 | 7.73B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Jan-05-24 | Initiated | Piper Sandler | Overweight |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Oct-17-23 | Initiated | Guggenheim | Buy |
Jun-08-23 | Initiated | BofA Securities | Neutral |
Oct-27-22 | Initiated | JP Morgan | Overweight |
May-23-22 | Initiated | SVB Leerink | Outperform |
Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-15-21 | Initiated | Goldman | Buy |
Nov-08-21 | Initiated | H.C. Wainwright | Buy |
Oct-28-21 | Initiated | Citigroup | Buy |
Oct-26-21 | Initiated | Cowen | Outperform |
Oct-26-21 | Initiated | Jefferies | Buy |
Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
(ROIV) Trading Advice - news.stocktradersdaily.com
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Yahoo Finance
(ROIV) Trading Signals - Stock Traders Daily
Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia
Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World
Trend Tracker for (ROIV) - Stock Traders Daily
Principal Financial Group Inc. Lowers Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Handelsbanken Fonder AB Trims Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Net worth of Vivek Ramaswamy: Roviant Sciences founder who is running for Ohio governor - Times of India
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board - The Manila Times
Early Warning Report Issued Pursuant to National Instrument 62?103: Roivant announces Resignation and Replacement of Arbutus Board - Lelezard
Roivant Sciences president Eric Venker sells $1.07 million in shares - Investing.com India
Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa
Roivant Sciences appoints new Principal Accounting Officer - Investing.com
Roivant Sciences Appoints New Chief Accounting Officer - TipRanks
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of Stock - MarketBeat
Long Term Trading Analysis for (ROIV) - Stock Traders Daily
Roivant Sciences’ chief accounting officer sells $2.37 million in shares - Investing.com India
Roivant Sciences' chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Canada
Roivant Sciences’ chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' chief accounting officer sells $2.37 million in shares - Investing.com
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 218,041 Shares - MarketBeat
Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN
Roivant Sciences president Eric Venker sells over $4.56 million in stock By Investing.com - Investing.com South Africa
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):